FactaeThe Factual News

Poxel announces end of phase 2 clinical trial for MASH on September 30

Poxel is completing its phase 2 clinical trial for MASH treatment.

Published 2h1 sourceNotableupdated 1h
Lire en français
≈ 17s

The fact

Results are expected by September 30, 2026.

This milestone is critical for the drug's development against metabolic steatohepatitis.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
FranceWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on August 24, 2026
← Back to home
Discover

Read more

All marches →
marches

Poxel presents results at EASD 2026 on Imeglimin

4j · 1 sourcemarches

Poxel hit by Merck payment halt: clinical timeline impact

11sem · 1 sourcemarches

Poxel postpones publication of its half-year financial results

3sem · 1 sourcemarches

Poxel secures Japanese patent for diabetes-targeting molecule

13sem · 1 sourcemarches

CAC 40 in wait-and-see mode before market reopening, several stocks decline

4h · 1 source